Clinical Trial

Evaluation of NWRD08 for HPV-16 and/or HPV-18 Related Cervical HSIL

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a randomized, double-blind, placebo controlled Phase 2 study to determine the efficacy and safety of NWRD08 administered by intramuscular (IM) injection followed by electroporation (EP) in adult women with histologically confirmed cervical high grade squamous intraepithelial lesion (HSIL) (cervical intraepithelial neoplasia grade 2 \[CIN2\] or grade 3 \[CIN3\]) associated with human papillomavirus (HPV) 16 and/or HPV18.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-09.
Status change: Not Yet Recruiting → Recruiting 2026-02-13
Trial Details
NCT Number NCT07175662
Lead Sponsor Newish Biotech (Wuxi) Co., Ltd.
Conditions High-grade Squamous Intraepithelial Lesion (HSIL)
Enrollment 150 participants
Start Date 2025-11-11
Primary Completion 2027-05-30 (estimated)
Study Completion 2027-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-17